FY2025 EPS Estimates for Abivax Raised by Lifesci Capital

Key Points

• Analysts at Lifesci Capital have increased their FY2025 earnings estimates for Abivax, predicting a loss of ($3.46) per share, up from ($3.50) previously, while maintaining an "Outperform" rating with a price target of $101.00.
• Several research firms, including Guggenheim and JMP Securities, have raised target prices for Abivax, with the consensus rating now being "Buy" and an average target price of $102.14.
• Despite positive earnings outlooks, Abivax's stock has recently experienced a 2.9% drop, opening at $82.40 after reaching a 52-week high of $92.91.

Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) - Analysts at Lifesci Capital raised their FY2025 earnings estimates for Abivax in a research note issued to investors on Monday, September 29th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($3.46) per share for the year, up from their previous estimate of ($3.50). Lifesci Capital has a "Outperform" rating and a $101.00 price objective on the stock. The consensus estimate for Abivax's current full-year earnings is ($2.83) per share.

Several other equities research analysts also recently commented on ABVX. Guggenheim upped their target price on shares of Abivax from $50.00 to $101.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. JMP Securities increased their target price on shares of Abivax from $95.00 to $114.00 and gave the stock a "market outperform" rating in a report on Thursday, September 25th. Morgan Stanley increased their target price on shares of Abivax from $71.00 to $101.00 and gave the stock an "overweight" rating in a report on Friday, September 12th. Leerink Partners set a $74.00 target price on shares of Abivax and gave the stock an "outperform" rating in a report on Wednesday, July 23rd. Finally, Wall Street Zen upgraded shares of Abivax from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat, Abivax has a consensus rating of "Buy" and an average target price of $102.14.

Abivax Stock Down 2.9%

Shares of NASDAQ:ABVX opened at $82.40 on Thursday. Abivax has a 52 week low of $4.77 and a 52 week high of $92.91. The company has a 50 day moving average price of $77.72 and a two-hundred day moving average price of $31.75.

Abivax (NASDAQ:ABVX - Get Free Report) last issued its earnings results on Monday, September 8th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.04.

Institutional Trading of Abivax

Hedge funds and other institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC grew its stake in shares of Abivax by 46.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company's stock worth $13,813,000 after acquiring an additional 696,626 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in Abivax by 3.3% during the first quarter. Nantahala Capital Management LLC now owns 1,482,994 shares of the company's stock valued at $9,269,000 after purchasing an additional 46,947 shares during the last quarter. Octagon Capital Advisors LP lifted its holdings in Abivax by 3.0% during the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company's stock valued at $9,693,000 after purchasing an additional 37,000 shares during the last quarter. Allostery Investments LP lifted its holdings in shares of Abivax by 86.0% in the first quarter. Allostery Investments LP now owns 1,099,654 shares of the company's stock worth $6,873,000 after buying an additional 508,401 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Abivax by 6.0% in the first quarter. Millennium Management LLC now owns 987,414 shares of the company's stock worth $6,171,000 after buying an additional 56,235 shares in the last quarter. Institutional investors own 47.91% of the company's stock.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.